Literature DB >> 17026867

Atopic eczema.

Matthias Möhrenschlager1, Johannes Ring.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17026867     DOI： 10.1007/s11882-006-0016-5

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN： 1529-7322            Impact factor:   4.919


× No keyword cloud information.
  27 in total

1.  Consensus statement on the safety profile of topical calcineurin inhibitors.

Authors:  T Bieber; M Cork; C Ellis; G Girolomoni; R Groves; R Langley; T Luger; M Meurer; D Murrell; S Orlow; A Paller; Y de Prost; L Puig; J Ring; J-H Saurat; T Schwarz; N Shear; G Stingl; A Taieb; K Thestrup-Pedersen
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

2.  Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.

Authors:  Lawrence F Eichenfield; Anne W Lucky; Mark Boguniewicz; Richard G B Langley; Robert Cherill; Katharine Marshall; Christopher Bush; Michael Graeber
Journal:  J Am Acad Dermatol       Date:  2002-04       Impact factor: 11.527

3.  Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis.

Authors:  Natalija Novak; Susanne Kruse; Stefan Kraft; Elisabeth Geiger; Hildegard Klüken; Rolf Fimmers; Klaus A Deichmann; Thomas Bieber
Journal:  J Invest Dermatol       Date:  2002-10       Impact factor: 8.551

4.  Treatment of eczema by EMG biofeedback and relaxation training: a multiple baseline analysis.

Authors:  C J McMenamy; R C Katz; M Gipson
Journal:  J Behav Ther Exp Psychiatry       Date:  1988-09

5.  The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.

Authors:  T Zuberbier; S U Chong; K Grunow; S Guhl; P Welker; M Grassberger; B M Henz
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

6.  The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study.

Authors:  U Darsow; J Laifaoui; K Kerschenlohr; A Wollenberg; B Przybilla; B Wüthrich; S Borelli; F Giusti; S Seidenari; K Drzimalla; D Simon; R Disch; S Borelli; A C A Devillers; A P Oranje; L De Raeve; J-P Hachem; C Dangoisse; A Blondeel; M Song; K Breuer; A Wulf; T Werfel; S Roul; A Taieb; S Bolhaar; C Bruijnzeel-Koomen; M Brönnimann; L R Braathen; A Didierlaurent; C André; J Ring
Journal:  Allergy       Date:  2004-12       Impact factor: 13.146

7.  The course of eczema in children aged 5-7 years and its relation to atopy: differences between boys and girls.

Authors:  M Möhrenschlager; T Schäfer; J Huss-Marp; B Eberlein-König; S Weidinger; J Ring; H Behrendt; U Krämer
Journal:  Br J Dermatol       Date:  2006-03       Impact factor: 9.302

8.  Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506).

Authors:  A Panhans-Gross; N Novak; S Kraft; T Bieber
Journal:  J Allergy Clin Immunol       Date:  2001-02       Impact factor: 10.793

9.  Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

Authors:  Sakari Reitamo; Edwin J M Van Leent; Vincent Ho; John Harper; Thomas Ruzicka; Kirsti Kalimo; Frédéric Cambazard; Malcolm Rustin; Alain Taïeb; David Gratton; Daniel Sauder; Graham Sharpe; Catherine Smith; Michael Jünger; Yves de Prost
Journal:  J Allergy Clin Immunol       Date:  2002-03       Impact factor: 10.793

10.  0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.

Authors:  S Reitamo; J Harper; J D Bos; F Cambazard; C Bruijnzeel-Koomen; P Valk; C Smith; C Moss; A Dobozy; R Palatsi
Journal:  Br J Dermatol       Date:  2004-03       Impact factor: 9.302
View more
  1 in total

1.  Environmental tobacco smoke and the risk of eczema symptoms among school children in South Africa: a cross-sectional study.

Authors:  Joyce Shirinde; Janine Wichmann; Kuku Voyi
Journal:  BMJ Open       Date:  2015-08-26       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.